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Abstract
Background: Preoperative SARS-CoV-2 vaccination could support safer elective surgery. Vaccine numbers are limited so this study
aimed to inform their prioritization by modelling.
Methods: The primary outcome was the number needed to vaccinate (NNV) to prevent one COVID-19-related death in 1 year. NNVs
were based on postoperative SARS-CoV-2 rates and mortality in an international cohort study (surgical patients), and community
SARS-CoV-2 incidence and case fatality data (general population). NNV estimates were stratified by age (18–49, 50–69, 70 or more
years) and type of surgery. Best- and worst-case scenarios were used to describe uncertainty.
Results: NNVs were more favourable in surgical patients than the general population. The most favourable NNVs were in patients
aged 70 years or more needing cancer surgery (351; best case 196, worst case 816) or non-cancer surgery (733; best case 407, worst
case 1664). Both exceeded the NNV in the general population (1840; best case 1196, worst case 3066). NNVs for surgical patients
remained favourable at a range of SARS-CoV-2 incidence rates in sensitivity analysis modelling. Globally, prioritizing preoperative
vaccination of patients needing elective surgery ahead of the general population could prevent an additional 58 687 (best case
115 007, worst case 20 177) COVID-19-related deaths in 1 year.
Conclusion: As global roll out of SARS-CoV-2 vaccination proceeds, patients needing elective surgery should be prioritized ahead of
the general population.
Introduction
The SARS-CoV-2 pandemic has disrupted elective surgery glob-
ally, with millions of elective operations either postponed or can-
celled1–3. Restriction of elective surgery activity was necessary
during periods of high COVID-19 hospital admissions in order to
divert hospital resources to ICUs4–6. However, in many countries,
owing to safety concerns, reductions in COVID-19 admissions
have been associated with only limited recovery of surgical serv-
ices1. Even in areas with low community SARS-CoV-2 infection
rates, surgical patients are at risk of nosocomial SARS-CoV-2 in-
fection7, which is associated with high rates of postoperative pul-
monary complications and death8,9. Although mitigation
measures, such as preoperative reverse transcription (RT)–PCR
swab screening and COVID-free surgical pathways, can reduce
the risk of COVID-19 complications7,10, they are unlikely to be
implemented universally, particularly in low- and middle-income
countries (LMICs).
Several SARS-CoV-2 vaccines have been authorized internation-
ally following phase III trials that demonstrated 100 per cent effec-
tiveness in preventing COVID-19-related deaths11–14. Preoperative
vaccination could support safe reinitiation of elective surgery by
significantly reducing the risk of COVID-19 complications in
patients undergoing elective procedures. However, it is projected
that the population in only 37 countries will have widespread
access to vaccination in 2021, with most LMICs only achieving
widespread coverage from late 2022 onwards15,16. Consequently,
throughout 2021, most governments will prioritize access to vacci-
nation to patients at greatest risk of COVID-19 mortality.
The benefits of SARS-CoV-2 vaccination in surgical patients
are currently unknown, and therefore governments are not prior-
itizing them for vaccination. The aim of this study was to inform
vaccination prioritization by modelling the impact of vaccination
on mortality in patients undergoing any type of inpatient elective
surgery.
Methods
This study explored the impact of SARS-CoV-2 vaccination in
adult patients (age at least 18 years) undergoing any type of elec-
tive inpatient surgery. The primary outcome was number needed
Received: February 07, 2021. Accepted: February 12, 2021
VC The Author(s) 2021. Published by Oxford University Press on behalf of BJS Society Ltd. All rights reserved.










/bjs/advance-article/doi/10.1093/bjs/znab101/6182412 by guest on 27 August 2021
to vaccinate (NNV) to prevent one COVID-19-related death over 1
year after SARS-CoV-2 vaccination, assuming that surgical
patients would receive the vaccination before operation. When
comparing NNV values for two different groups, the lower NNV
value is more favourable, as this indicates that fewer people in
that group need to be vaccinated in order to prevent one death.
The secondary outcomes were NNV to prevent one COVID-19-re-
lated death over 30 days after SARS-CoV-2 vaccination, and addi-
tional COVID-19-related deaths prevented by prioritizing
preoperative vaccination for surgical patients versus age-
matched controls..
As SARS-CoV-2 mortality is strongly associated with age17–19,
NNV estimates were preplanned to be stratified by age group
(18–49 years, 50–69 years, 70 years or more). In addition, as priori-
tization and planning of cancer and non-cancer surgery differs,
NNV estimates were also preplanned to be stratified by indication
for surgery (cancer versus non-cancer). To contextualize the NNV
estimates for surgical patients, age-stratified NNVs were also
estimated for the general population. The study was registered at
Clinical.Trials.gov (NCT0450998690).
Modelling strategy
NNVs in surgical patients were based on postoperative SARS-
CoV-2 rates and mortality from the multinational multicentre
GlobalSurg–CovidSurg Week study. NNVs in the general popula-
tion were based on global community SARS-CoV-2 incidence and
UK SARS-CoV-2 case fatality data. It was assumed that, outside
of the initial 30-day postoperative window, during the following
335 days surgical patients are at the same risk of SARS-CoV-2
infection and SARS-CoV-2 mortality as the general population
within the same age group.
The following equation was used to calculate NNV to prevent
one COVID-19-related death over 1 year after SARS-CoV-2 vacci-
nation in the surgical groups:
NNV ¼ 1=

Sþ ðD 335 CÞ

where S is postoperative mortality (within 30 days after surgery)
attributable to SARS-CoV-2 infection, D is the daily community
SARS-CoV-2 incidence, and C is the case fatality rate for SARS-
CoV-2 in the general population.
To calculate the NNV to prevent one death over 1 year after
vaccination in the general population, the equation was:
NNV ¼ 1=ðD 365 CÞ:
GlobalSurg–CovidSurg Week study
Real-world estimates for postoperative SARS-CoV-2 rates and
postoperative mortality attributable to SARS-CoV-2 were based
on the GlobalSurg-CovidSurg Week study. This was an interna-
tional prospective multicentre cohort study (NCT04509986) that
included patients undergoing any type of surgical procedure per-
formed routinely in an operating theatre by a surgeon.
Participating centres collected data on all consecutive patients in
one or more preselected surgical specialties during 1 or more
weeks within an overall 28-day study window (5 October 2020 to
1 November 2020). Patients who had either elective surgery
(planned admission to hospital) or emergency surgery
(unplanned admission), as either an inpatient (surgery with a
planned overnight stay) or day case, were included. This analysis
was restricted to patients having elective inpatient surgery.
Mortality status was determined by 30-day postoperative follow-
up. Patients with data missing on age, sex, ASA physical status
grade, indication for surgery, grade of surgery, SARS-CoV-2 infec-
tion status, or mortality were excluded from this analysis, to al-
low consistent denominators throughout calculations.
The study collected only routine, anonymized data with no
change to clinical care pathways. A secure online REDCap data-
base was used for data collection. The study was registered at
each participating hospital in line with applicable regulations. In
the UK, the study was registered as either a clinical audit or ser-
vice evaluation (registration reference at lead site, University
Hospitals Birmingham NHS Foundation Trust: CARMS-16328).
Postoperative mortality attributable to
SARS-CoV-2
The proportion of patients who died within 30 days of surgery
with death attributable to a postoperative SARS-CoV-2 infection
was calculated as I  R, where I is the postoperative SARS-CoV-2
rate in the first 30 days after surgery, and R is the postoperative
SARS-CoV-2 attributable mortality (an adjusted estimate for the
difference in mortality between patients who did and did not
have postoperative SARS-CoV-2 infection).
Postoperative SARS-CoV-2 rates
In the GlobalSurg–CovidSurg Week study, postoperative SARS-
CoV-2 was defined as any diagnosis of SARS-CoV-2 made after
surgery, up to and including postoperative day 30. This included
both patients with and without symptoms. SARS-CoV-2 could
be diagnosed based on a positive RT–PCR swab, positive rapid
antigen test, positive chest CT, and/or contemporaneous clinical
diagnosis (in the absence of negative RT–PCR swab results).
Patients who had a diagnosis of SARS-CoV-2 at any time before
surgery were excluded from the denominator for calculating
postoperative SARS-CoV-2 rates.
Postoperative SARS-CoV-2 attributable mortality
Multiple studies have established that patients who become
infected with SARS-CoV-2 after operation are at increased risk of
postoperative death8,9. However, there are likely to be confound-
ing factors, with higher postoperative mortality rates in SARS-
CoV-2-infected patients partly attributable to baseline differen-
ces such as older age or co-morbidity. Therefore, an unadjusted
risk difference for mortality between patients with and without
postoperative SARS-CoV-2 infection is likely to overestimate
mortality attributable to SARS-CoV-2.
To reduce confounding, data for elective inpatient surgery
from the GlobalSurg–CovidSurg Week study were used to esti-
mate adjusted differences in mortality between patients who did
and did not have postoperative SARS-CoV-2. This was based on
average marginal effects taken from multilevel logistic regression
models. The outcome in the models was 30-day mortality.
As well as postoperative SARS-CoV-2 infection, the models were
adjusted for factors that have previously been identified as
independent predictors of death in patients with perioperative
SARS-CoV-2 infection8: age, sex, ASA physical status grade
(grades I–II versus III–V), indication (surgery for benign versus ma-
lignant disease), and grade of surgery (minor versus major, based
on the BUPA schedule of procedures20). In addition, country was
included as a random effect, with hospital nested within country.
Models were stratified by age subgroup (20–49 years, 50–69 years,
70 years or more). Analyses were completed in StataVR version 15.1
(StataCorp, College Station, Texas, USA).
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Daily community SARS-CoV-2 incidence
Daily community SARS-CoV-2 incidence was based on SARS-
CoV-2 cases reported globally in 202021. Countries were split into
tertiles by community SARS-CoV-2 incidence rank. Median daily
community SARS-CoV-2 incidence was calculated for each tertile
to produce values for low, medium, and high community SARS-
CoV-2 incidence. The main analysis was based on medium SARS-
CoV-2 incidence.
Case fatality rates in the general population
Age-stratified SARS-CoV-2 case fatality rates in the general popu-
lation were calculated using SARS-CoV-2 seroprevalence and
mortality data from England. The full methodology is described
in Appendix S1.
Vaccine effectiveness
No deaths from COVID-19 have been reported beyond 1 week af-
ter SARS-CoV-2 vaccination in the phase III trials published to
date11–14. The main analysis was therefore based on SARS-CoV-2
vaccination being 95 per cent effective in preventing death from
COVID-19.
COVID-19-related deaths prevented
The number of additional COVID-19-related deaths that could be
prevented in 1 year by vaccinating surgical patients before opera-
tion rather than the general population was calculated by sub-
tracting the number of COVID-19-related deaths that would
occur over 30 days in the unvaccinated general population from
the number of COVID-19-related deaths that would occur in first
30 postoperative days in unvaccinated surgical patients.
Estimates were age-stratified (Appendix S1).
Sensitivity analyses for community SARS-CoV-2
incidence
NNV values vary depending on local SARS-CoV-2 incidence.
Therefore, a significant area of uncertainty concerns SARS-CoV-2
incidence in the general population, as this varies across both
geographical regions and time. Future variation may reflect
changes in government policies, or the emergence of new viral
strains with either increased or decreased transmissibility. One-
way sensitivity analyses were therefore undertaken, applying the
low and high community SARS-CoV-2 incidence estimates.
Best- and worst-case scenarios
Best- and worst-case scenarios were produced to further explore
uncertainty. The best-case scenario represents the lowest likely
value for NNV and the highest likely value for additional COVID-
19-related deaths prevented, whereas the worst-case scenario
represents the highest likely value for NNV and the lowest likely
value for additional COVID-19-related deaths prevented. The
parameters for the best- and worst-case scenarios are described
in Appendix S1 and summarized in Table 1.
Results
GlobalSurg–CovidSurg week study
Overall, the GlobalSurg–CovidSurg Week study captured data for
141 582 patients from across 1667 hospitals in 116 countries. Of
the 89 225 adults who underwent elective surgery, 31 434 had a
day-case procedure and 1202 had a preoperative SARS-CoV-2
infection. Therefore, 56 589 patients were included in the
main analyses (Fig. S1). A demographic breakdown is provided in
Table 2.
Postoperative SARS-CoV-2 rates
The overall postoperative SARS-CoV-2 rate was 0.96 per cent (541
of 56 589). Incidence by subgroup is shown in Table S1. Overall,
504 of 541 diagnoses (93.2 per cent) were based on a positive RT–
PCR (495) or positive rapid antigen test (15). A further 19 patients
(3.5 per cent) had a positive chest CT, and the remaining 18 (3.3
per cent) had a clinical diagnosis.
Postoperative SARS-CoV-2 attributable mortality
In adjusted multilevel models, SARS-CoV-2 infection was signifi-
cantly associated with 30-day postoperative mortality across all
age groups (Table 3). Adjusted differences in 30-day mortality be-
tween patients with and without postoperative SARS-CoV-2 in-
fection were calculated from these models and are presented in
Table 4.
NNV to prevent one COVID-19-related death over
1 year
In the main analysis, NNVs to prevent one COVID-19-related
death over 1 year were lower for surgical patients than the gen-
eral population in all age groups (Fig. 1). NNVs were lowest in
people aged at least 70 years: 351 (196 for best-case, 816 for
worst-case scenario) among those needing cancer surgery, 733
Table 1 Parameters used for main analysis, and best- and worst-case scenarios
Worst-case scenario Main analysis Best-case scenario
Postoperative SARS-
CoV-2 rates
Based on lower bound of 95% confi-
dence interval for 30-day postop-
erative SARS-CoV-2 rates
Based on point estimate for 30-day
postoperative SARS-CoV-2 rates
Based on upper bound of 95% confi-





Based on lower bound of 95% confi-
dence interval for adjusted differ-
ence in 30-day mortality
Based on point estimate for adjusted
difference in 30-day mortality
Based on upper bound of 95% confi-
dence interval for adjusted differ-
ence in 30-day mortality
Community SARS-
CoV-2 infection rates
All scenarios modelled based on medium SARS-CoV-2 incidence. Separate one-way sensitivity analyses performed





Based on upper bound of 95% credi-
ble intervals published by ONS for
new SARS-CoV-2 cases per day
Based on point estimate published
by ONS for new SARS-CoV-2 cases
per day
Based on lower bound of 95% credi-
ble intervals published by ONS for
new SARS-CoV-2 cases per day
SARS-CoV-2 vaccine ef-
fectiveness
Based on vaccination having 100%
effectiveness in preventing
COVID-19-related deaths
Based on vaccination having 95% ef-
fectiveness in preventing COVID-
19-related deaths
Based on vaccination having 80% ef-
fectiveness in preventing COVID-
19-related deaths
* Based on adjusted differences in 30-day mortality between patients with and without postoperative SARS-CoV-2 infection. ONS, Office for National Statistics.
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(407, 1664) for those needing non-cancer surgery, and 1840 (1196,
3066) for the general population. However, NNVs in patients aged
50–69 years needing either cancer surgery (559; 304, 1482) or non-
cancer surgery (1621; 854, 4577) were favourable compared with
the NNV for the general population aged 70 years or more.
In sensitivity analyses modelling both low and high commu-
nity SARS-CoV-2 infection rates, NNVs for surgical patients
remained favourable (Table 5). Across all countries, there was an
advantage to prioritizing surgical patients (Fig. 2). Relative to the
general population, vaccination of surgical patients had the









Age (years) < 0.001
18–29 5512 (25.2) – –
30–39 7898 (36.2) – –
40–49 8426 (38.6) – –
50–59 – 10 204 (47.3) –
60–69 – 11 373 (52.7) –
70–79 – – 9491 (72.0)
 80 – – 3685 (28.0)
Sex < 0.001
F 7827 (35.8) 10 959 (50.8) 6148 (46.7)
M 14009 (64.2) 10 618 (49.2) 7028 (53.3)
ASA physical status grade < 0.001
I–II 19 373 (88.7) 14 801 (68.6) 6370 (48.3)
III–V 2463 (11.3) 6776 (31.4) 6806 (51.7)
Indication < 0.001
Non-cancer surgery 18 241 (83.5) 13 906 (64.4) 7932 (60.2)
Cancer surgery 3595 (16.5) 7671 (35.6) 5244 (39.8)
Grade of surgery
Minor 5564 (25.5) 5063 (23.5) 3132 (23.8) < 0.001
Major 16 272 (74.5) 16 514 (76.5) 10 044 (76.2)
Postoperative SARS-CoV-2 < 0.001
No 21 676 (99.3) 21 347 (98.9) 13 025 (98.9)
Yes 160 (0.7) 230 (1.1) 151 (1.1)
30-day mortality < 0.001
No 21 750 (99.6) 21 362 (99.0) 12 946 (98.3)
Yes 86 (0.4) 215 (1.0) 230 (1.7)
Values in parentheses are percentages. Patients with a preoperative diagnosis of SARS-CoV-2 were excluded (Fig. S1). *v2 test.
Table 3 Age-stratified adjusted multilevel models for 30-day mortality in elective inpatient surgery patients
18–49 years 50–69 years 70 years
Odds ratio P Odds ratio P Odds ratio P
Age (years)
18–29 1.00 (reference) – –
30–39 0.69 (0.37, 1.29) 0.239 – –
40–49 0.99 (0.56, 1.73) 0.968 – –
50–59 – 1.00 (reference) –
60–69 – 1.22 (0.91, 1.64) 0.190 –
70–79 – – 1.00 (reference)
 80 – – 1.66 (1.25, 2.20) < 0.001
Sex
F 1.00 (reference) 1.00 (reference) 1.00 (reference)
M 1.45 (0.93, 2.26) 0.102 1.17 (0.87, 1.57) 0.299 1.51 (1.14, 2.01) 0.004
ASA physical status grade
I–II 1.00 (reference) 1.00 (reference) 1.00 (reference)
III–V 6.69 (4.19, 10.69) < 0.001 5.24 (3.79, 7.24) < 0.001 4.44 (3.09, 6.38) < 0.001
Indication
Non-cancer surgery 1.00 (reference) 1.00 (reference) 1.00 (reference)
Cancer surgery 3.92 (2.45, 6.27) < 0.001 2.07 (1.53, 2.82) < 0.001 1.85 (1.39, 2.46) < 0.001
Grade of surgery
Minor 1.00 (reference) 1.00 (reference) 1.00 (reference)
Major 1.19 (0.67, 2.10) 0.546 1.04 (0.72, 1.52) 0.824 1.52 (1.05, 2.19) 0.027
Postoperative SARSCoV-2
No 1.00 (reference) 1.00 (reference) 1.00 (reference)
Yes 4.07 (1.18, 14.13) 0.027 11.52 (6.30, 21.09) < 0.001 10.31 (6.18, 17.20) < 0.001
Values in parentheses are 95 per cent confidence intervals. Separate multilevel models were created for each age group. This analysis was adjusted for age, sex,
ASA grade, surgical indication, grade of surgery, and postoperative SARS-CoV-2 infection, with country and hospital effects included. Unadjusted models are shown
in Tables S2–S4.
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greatest advantage in countries with low community SARS-CoV-
2 infection rates.
NNV to prevent one COVID-19-related death over
30 days
Within each age group, NNVs to prevent one COVID-19-related
death over 30 days were lower for surgical patients than for the
general population, regardless of community SARS-CoV-2 inci-
dence (Table 6). Across age groups, NNVs were lowest in people
aged 70 years or more: 425 (231 for best-case, 1080 for worst-case
scenario) for those needing cancer surgery, 1157 (592, 3316) for
those needing non-cancer surgery, and 22 384 (14 552, 37 302) for
the general population.
COVID-19-related deaths prevented
Globally, a policy of preoperative vaccination of patients aged
70 years or more before elective surgery in preference to age-
matched general populations was projected to prevent an addi-
tional 26 624 (9865 for worse-case, 50 410 for best-case
scenario) COVID-19-related deaths in 1 year, assuming that
global surgical activity was at 75 per cent of prepandemic vol-
ume (Table S7). Prioritizing all surgical patients for preoperative
vaccination ahead of the general population was projected to
prevent an additional 58 687 (20 177, 115 007) COVID-19-related
deaths.
Discussion
This study used real-world data from an international, prospec-
tive cohort study to model NNVs to prevent COVID-19-related
deaths among patients needing elective inpatient surgery. When
compared within age groups, NNVs were consistently lower for
surgical patients than for the general population. NNVs were par-
ticularly favourable for patients needing cancer surgery, who are
likely to be prioritized for elective surgery as services restart in
2021. These findings were consistent across all settings regard-
less of community SARS-CoV-2 infection rates, as well as in best-
and worst-case scenario analyses.
SARS-CoV-2 vaccination could prevent tens of thousands of
COVID-19-related postoperative deaths. However, vaccine sup-
plies are likely to remain limited in most countries throughout
202116. Most governments are therefore prioritizing vaccination
for groups at highest risk of COVID-19 mortality22. This modelling
study can inform prioritization of surgical patients within vacci-
nation plans. It supports prioritization of patients aged 70 years
or more needing elective surgery alongside other high-risk groups
during early vaccination programmes. Once vaccines are rolled
Table 4 Adjusted differences in 30-day mortality rate between
patients with and without postoperative SARS-CoV-2 infection
Adjusted difference in
30-day mortality rate (%)
Age 18–49 years
Elective non-cancer surgery 0.77 (0, 2.00)
Elective cancer surgery 2.63 (0, 6.60)
Age 50–69 years
Elective non-cancer surgery 7.26 (3.38, 11.14)
Elective cancer surgery 11.55 (6.08, 17.02)
Age  70 years
Elective non-cancer surgery 10.46 (5.56, 15.36)
Elective cancer surgery 15.84 (9.30, 22.39)
Values in parentheses are 95 per cent confidence intervals; if the lower bound
of the 95 per cent confidence interval included negative values, this was
reported as 0 per cent. Adjusted differences were calculated using average
marginal effects, based on multilevel models (including country and hospital
effects) that were adjusted for age, sex, ASA physical status grade, indication
for operation (cancer versus non-cancer surgery), and grade of surgery (minor
versus major).
1 10 100 1,000 10,000 100,000 1,000,000
Elective inpatient surgery: cancer
Elective inpatient surgery: non-cancer
General population
Age 18–49 years
Elective inpatient surgery: cancer
Elective inpatient surgery: non-cancer
General population
Age 50–69 years
Elective inpatient surgery: cancer
Elective inpatient surgery: non-cancer
General population
Age ≥70 years
No. needed to vaccinate to prevent one death over 1 year
Fig. 1 Global number needed to vaccinate to prevent one COVID-19-related death over 1 year
Number needed to vaccinate estimates for the general population are based on global SARS-CoV-2 infection rates (26.48 per million people per day); estimates
assume that this remains steady for a full year. For surgical patients, estimates are based on preoperative vaccination. Error bars indicate estimates for best- and
worst-case scenarios. Data are presented on a logarithmic scale.
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out to the wider population, it will be advantageous to
prioritize surgical patients, particularly those undergoing cancer
surgery.
Implementation of vaccination for surgical patients will re-
quire the development of preoperative pathways to deliver vacci-
nation ahead of planned surgery dates. These pathways should
be designed alongside wider system developments aimed at re-
ducing nosocomial SARS-COV-2 transmission, such as preopera-
tive SARS-CoV-2 swab testing and COVID-free surgical
pathways7,10. Future research should evaluate which of the li-
censed vaccines is most effective in surgical patients and the op-
timal timing for preoperative vaccination.
There may be additional benefits to vaccinating surgical
patients. Up to 70 per cent of elective procedures were postponed
during the first wave of the SARS-CoV-2 pandemic, resulting in
an estimated 28 million elective operations being delayed or can-
celled2,3. Although elective surgery volumes have started to re-
cover in many countries, ongoing disruption is likely to continue
throughout 2021, particularly in the event of countries experienc-
ing further SARS-CoV-2 waves. Prioritization of SARS-CoV-2 vac-
cination for surgical patients could support safe reinitiation of
elective surgery services, especially in regions where vaccinating
the total population will take several years. In addition, SARS-
CoV-2 vaccination is likely to decrease postoperative pulmonary
complications, reducing intensive care use and overall healthcare
costs.
This study has limitations. First, NNV estimates should be
interpreted with caution. Although NNVs for surgical patients are
advantageous compared with those for the general population in
sensitivity analyses for both low and high SARS-CoV-2 infection
rates, precise NNV values fluctuate depending on prevailing
SARS-CoV-2 infection rates; the higher the SARS-CoV-2 inci-
dence, the fewer people need to be vaccinated to prevent one
SARS-CoV-2 infection, so the more favourable (lower) the NNV
becomes. Second, NNV estimates were based on postoperative
SARS-CoV-2 infection rates taken from a global snapshot in
October 2020, and it is unknown how these rates vary over time
and across regions. Third, SARS-CoV-2 case fatality rates were
based on data from England and it is unknown how generalizable
these are, although they are broadly consistent with other pub-
lished data (Appendix S1). Finally, vaccine effectiveness was mod-
elled based on the limited data available from trials performed in
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Fig. 2 Estimates for number needed to vaccinate to prevent one COVID-19-related death over 1 year, based on country-specific SARS-COV-2
community infection rates, stratified by age
a 18–49 years, b 50–69 years, and c 70 years or more. Number needed to vaccinate is plotted on a logarithmic scale.
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Table 6 Sensitivity analyses for surgical patients needing elective non-cancer or cancer surgery, and low, medium, and high
community SARS-CoV-2 incidence in the general population, showing number needed to vaccinate to prevent one COVID-19-related
death over 30 days
NNV to prevent one death over 30 days
18–49 years 50–69 years 70 years
Surgical patients*













Low SARS-CoV-2 incidence 41 105 752
(26 723 608, 68 503 312)
2 701 335
(1 756 188, 4 501 746)
385 581
(250 673, 642 566)
Medium SARS-CoV-2 incidence 2 386 263
(1 551 354, 3 976 683)
156 817
(101 950, 261 335)
22 384
(14 552, 37 302)
High SARS-CoV-2 incidence 524 238
(340 817, 873 637)
34 451
(22 397, 57 413)
4917
(3197, 5689)
Values in parentheses are results for best- and worst-case scenarios. All parameters other than SARS-CoV-2 incidence are based on the main analysis. *A single set
of estimates is provided for surgical patients, because SARS-CoV-2 infection rates within 30 days of surgery were modelled from rates observed in the GlobalSurg–
CovidSurg Week study, so this was independent of community SARS-CoV-2 rates. †As there is no postoperative mortality attributable to SARS-CoV-2 infection in
the worst-case scenario for patients aged 18–49 years (Table 4), in the worst-case scenario there would be no benefit from vaccinating these patients. NNV, number
needed to vaccinate; n.a., not applicable.
Table 5 Sensitivity analyses for low, medium, and high community SARS-CoV-2 incidence, showing number needed to vaccinate to
prevent one COVID-19-related death over 1 year
NNV to prevent one death over 1 year
18–49 years 50–69 years 70 years
Low SARS-CoV-2 incidence
General population 3 378 555
(2 196 461, 5 630 327)
222 028
(144 344, 370 007)
31 692
(20 603, 52 814)
Elective non-cancer surgery 20 049





Elective cancer surgery 3991






General population 196 131


















General population 43 088

















Values in parentheses are results for best- and worst-case scenarios. Estimates assume that the community SARS-CoV-2 incidence remains at a steady rate for a
full year. All parameters other than SARS-CoV-2 incidence are based on the main analysis. NNV, number needed to vaccinate.
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